Specifically, using the hAPP(751)SL transgenic mouse model of AD, the ability of chronic administration (4 month) of two NADPH oxidase inhibitors (apocynin and DM) to prevent toxic microglial activation, reduce plaque size, preserve neuron function, and attenuate cumulative learning and memory deficits was tested. Here, FMO5 is linked to Alzheimer disease.